Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

prnasiaOctober 13, 2021

Tag: Emmaus Life Sciences , IRAK4 , KM10544

PharmaSources Customer Service